Información del producto
- (4R,6S)-6-[(1E)-2-[2-(Cyclopropyl-d5)-4-(4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one
- [4R-[4a,6ß(E)]]-6-[2-[2-(Cyclopropyl-d5)-4- (4-fluorophenyl)-3-quinolinyl]ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-one
- NK 104-d5
- NK 104-d5 (lactone)
- Nisvastatin-d5
- P 872441-d5
- 4-(1-(4-Chlorobenzoyl)-6-imino-3-methyl-1,4,6,7-tetrahydropyrazolo[3,4-d][1,3]thiazin-4-yl)-2-methoxyphenol
- 4H-Pyrazolo[3,4-d][1,3]thiazin-6-amine, 1-(4-chlorobenzoyl)-4-(4-hydroxy-3-methoxyphenyl)-3-methyl-
- [6-amino-4-(4-hydroxy-3-methoxyphenyl)-3-methylpyrazolo[3,4-d][1,3]thiazin-1(4H)-yl](4-chlorophenyl)methanone
- (4R,6S,E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl-ethenylvinyl]-4-hydroxyl-3,4,5,6-H-2H-pyran-2-etone
- Ver más sinónimos
- Pitavastatin calcium intermediates to 5,(4R,6S,E)-6-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinoline-yl-vinyl]-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
Applications A labelled metabolite of Pitavastatin. Recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms. The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells.
References Wang, J., et al.: Drug Metab. Dispos., 30, 1352 (2002), Yamada, I., et al.: Xenobiotica, 33, 789 (2003), Fujino, H., et al.: Xenobiotica, 34, 961 (2004), Ando, H., et al.: Br. J. Clin. Pharmacol., 60, 494 (2005),
Propiedades químicas
Consulta técnica sobre: TR-P531022 Pitavastatin-d5 Lactone
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.